# Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)

> **NCT01531387** · PHASE3 · TERMINATED · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 38 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** Hydroxyurea

## Key facts

- **NCT ID:** NCT01531387
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** inability to reach a satisfactory endpoint with respect to adequate recruitment
- **Last updated:** 2016-02-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01531387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01531387, "Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01531387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*